A ground-breaking method for predicting bowel cancer among those at higher risk has achieved over 90% accuracy, according to recent research.
In the UK, around 500,000 individuals suffer from inflammatory bowel disease (IBD), including conditions like Crohn’s disease and ulcerative colitis. These patients are routinely screened for pre-cancerous growths, which traditionally signal a 30% likelihood of developing bowel cancer within a decade.
However, new research from the UK has identified specific DNA changes in these pre-cancerous cells. When analyzed with a new algorithm, these changes can predict with over 90% accuracy who among IBD patients will develop bowel cancer in the next five years.
The study involved analyzing tissue samples from IBD patients, with hopes that this approach could lead to the development of a simple blood test to pinpoint those at greatest risk.
Craig Foster, whose wife Fariba passed away from bowel cancer in February 2024, shared:
“Research like this will save lives. Fariba had ulcerative colitis since she was 18, and she lost three-quarters of her bowel to it. Knowing scientists are working on this gives me comfort, ensuring others don’t face the same ordeal.”
Professor Trevor Graham from the Institute of Cancer Research in London commented:
“Most people with ulcerative colitis or Crohn’s won’t get bowel cancer, but for those showing signs of pre-cancer, there are difficult choices. They can either opt for regular monitoring or choose to have their bowel removed. Our test aims to provide better information for decision-making, reducing the uncertainty for both patients and doctors.”
Marianne Radcliffe from Crohn’s & Colitis UK highlighted:
“This research is a beacon of hope for those living with these conditions. The uncertainty of life with Crohn’s or colitis is daunting, and early detection through less invasive methods is incredibly promising.”
Dr. Iain Foulkes from Cancer Research UK, which funded the study, added:
“Advancements like genome sequencing are changing how we diagnose and understand cancer. This research allows us to concentrate our efforts and resources on those at the highest risk, offering reassurance to others and potentially saving lives and healthcare costs.”
This study underscores the potential of personalized medicine in managing chronic conditions like IBD and improving outcomes for those at risk of bowel cancer.
Tell us your thoughts in the Facebook post and share this with your friends.
